🔬 General ResearchPublished: August 19, 2026

Tesamorelin: Targeted Growth Hormone-Releasing Factor (GHRF) Analogue & Pituitary Somatotroph Dynamics

“Tesamorelin (TH9507) is a stabilized 44-amino-acid synthetic analogue of human growth hormone-releasing factor (GHRF 1-44) modified with an N-terminal trans-3-hexenoyl group, investigated for physiological pulsatile GH release, hepatic IGF-1 synthesis, and visceral adipose tissue catabolism.”

Consult Analyst Research Database

Legal & Laboratory Compliance Notice

FOR IN-VITRO LABORATORY RESEARCH ONLY: This scientific publication is provided strictly for academic and biochemical reference by certified researchers. Materials and compounds referenced are NOT for human consumption, veterinary use, drug manufacture, or direct clinical administration. Statements have not been evaluated by Health Canada or the FDA.

Scientific Research Overview

Abstract & Executive Summary

Tesamorelin (developmental code name TH9507) is a synthetic 44-amino-acid peptide analogue of human Growth Hormone-Releasing Hormone (GHRH / GHRF 1-44). While native human GHRH(1-44) is rapidly degraded in systemic circulation by Dipeptidyl Peptidase-4 (DPP-4) with a terminal half-life of less than 10 minutes, Tesamorelin is engineered with an N-terminal trans-3-hexenoic acid moiety that provides enzymatic resistance while retaining full bioactivity at the pituitary GHRH receptor.

Tesamorelin selectively stimulates anterior pituitary somatotrophs to synthesize and secrete growth hormone (GH) in a natural, pulsatile manner. Because it stimulates endogenous production rather than delivering exogenous recombinant human GH (rhGH), it preserves normal negative feedback regulation mediated by somatostatin and circulating IGF-1, avoiding supraphysiological continuous GH exposure and severe insulin resistance.

+----------------------------------------------------------------------------------------------------+
|                                    TESAMORELIN SOMATOTROPIC CASCADE                                |
+------------------------------------+----------------------------------+-----------------------------+
| Pituitary GHRHR Binding            | Pulsatile GH Secretion           | Target Tissue Actions       |
| - Gs-protein adenylyl cyclase      | - Retains somatostatin feedback  | - Hepatic IGF-1 generation  |
| - Intracellular cAMP/PKA activation| - Episodic physiological peaks   | - Hormone-Sensitive Lipase  |
| - L-type Ca2+ channel opening      | - Pit-1 de novo gene synthesis   | - Selective Visceral Fat Loss|
+------------------------------------+----------------------------------+-----------------------------+

Chemical Structure & Molecular Specifications

Amino Acid Sequence:

[trans-3-hexenoyl]-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2

Molecular Formula: C221H366N72O67S

Molecular Weight: 5135.86 g/mol

CAS Registry Number: 218949-48-5

Structural Hallmark: The N-terminal trans-3-hexenoyl modification caps the tyrosine amino terminus, preventing DPP-4 from cleaving the N-terminal Tyr1-Ala2 dipeptide.

Mechanism of Action

Tesamorelin operates through selective receptor binding and downstream intracellular signaling in anterior pituitary somatotrophs:

1. GHRH Receptor (GHRHR) Binding & cAMP/PKA Activation

Tesamorelin binds specifically to the GHRH receptor (a Gs-coupled GPCR) on the surface of pituitary somatotrophs:

Receptor activation stimulates membrane-associated Adenylyl Cyclase (AC), rapidly increasing intracellular cAMP concentrations.

Elevated cAMP activates Protein Kinase A (PKA) and exchange proteins directly activated by cAMP (Epac).

2. Voltage-Gated Calcium Influx & Granule Exocytosis

Activated PKA phosphorylates voltage-dependent L-type Ca2+ channels, driving rapid extracellular calcium influx:

Intracellular calcium mobilization triggers the fusion of pre-synthesized growth hormone storage granules with the cell membrane, releasing pulsatile bursts of GH into the hypophyseal portal circulation.

3. De Novo GH Gene Transcription (Pit-1 Activation)

PKA catalytic subunits translocate to the nucleus and phosphorylate the cAMP Response Element-Binding Protein (CREB):

Phosphorylated CREB activates the pituitary-specific POU-domain transcription factor Pit-1 (POU1F1).

Pit-1 binds to the human growth hormone gene promoter, driving de novo transcription and replenishment of somatotroph GH stores.

4. Visceral Adipocyte Lipolysis & Hepatic IGF-1 Induction

Pulsatile GH released by Tesamorelin exerts targeted peripheral metabolic actions:

Visceral Adipocytes: GH activates Hormone-Sensitive Lipase (HSL) and downregulates Lipoprotein Lipase (LPL), selectively mobilizing triglycerides from metabolically active visceral adipose tissue (VAT).

Hepatocytes: GH binds to hepatic Growth Hormone Receptors (GHR), activating the JAK2/STAT5b pathway to transcribe Insulin-Like Growth Factor 1 (IGF-1) and IGFBP-3.

Key Study Highlights

✓

N-Terminal Hexenoyl Stabilization

trans-3-hexenoyl modification confers robust resistance against DPP-4 degradation.

✓

Pulsatile GH Release

Preserves natural somatotropic feedback loops without continuous receptor desensitization.

✓

Visceral Adipose Mobilization

Selectively drives lipolysis in visceral fat depots, resolving abdominal lipodystrophy.

✓

Pit-1 Transcription Factor Induction

Stimulates de novo growth hormone gene transcription in anterior pituitary cells.

Scientific FAQs

Exogenous rhGH creates constant, non-physiological blood levels that suppress the pituitary and can cause severe insulin resistance. Tesamorelin stimulates the pituitary to release endogenous GH in natural pulses, maintaining feedback regulation.

Molecular Formula: C221H366N72O67S, Molecular Weight: 5135.86 g/mol, CAS Number: 218949-48-5.

Reconstitute with sterile Bacteriostatic Water (0.9% benzyl alcohol). Store lyophilized vials at -20°C. Once reconstituted, refrigerate at 2-8°C and use within 28 days.

References

Falutz J. et al (2007).
Effects of tesamorelin on visceral adipose tissue
N Engl J Med, 357(23):2359-2370
View Research Paper ↗
Stanley T.L. et al (2019).
Effects of tesamorelin on hepatic steatosis in NAFLD
Lancet HIV, 6(12):e821-e830
View Research Paper ↗

Procure Research Reference Materials

Access laboratory-grade reference compounds with verified batch HPLC purity reports and sterility documentation.

View Compound Specifications

Literature Inquiries

Have questions about the pre-clinical citations or chemical parameters detailed in this research? Connect with our analytical representatives.

Contact Researchers